09/06/21 -"Our target price hike is largely attributable to an increase in our peer-based valuations, as we have factored in a premium of 20% vs none earlier. We believe, given the recovery from the quality ..."
Pages
58
Language
English
Published on
09/06/21
You may also be interested by these reports :
18/04/24
While the near-term performance is expected to be impacted by various challenges, there are still some promising takeaways from our recent discussion ...
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...